784 results on '"Park, Y.H."'
Search Results
2. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer
4. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
5. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
6. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
7. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
8. Quality characteristics and storage stability of pork patties added with drone pupae (Apis mellifera) powder.
9. Irreversible electroporation for localized prostate cancer: Prospective cohort study evaluating local tumor control and quality of life
10. Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography
11. An overview of solar still enhancement approaches for increased freshwater production rates from a thermal process perspective
12. Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
13. Investigations on the performance of piezoelectric-flexoelectric energy harvesters
14. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
15. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
16. RWD55 Retrospective Observational Study of Real-World Treatment Patterns and Financial Burden in Patients With Premenopausal Metastatic HR+/HER2- Breast Cancer
17. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
18. Enhanced high-temperature mechanical properties of ARAA by thermo-mechanical processing
19. Characterization of silk hydrogel formed with hydrolyzed silk fibroin-methacrylate via photopolymerization
20. Optimization of a fermented pumpkin-based beverage to improve Lactobacillus mali survival and α-glucosidase inhibitory activity: A response surface methodology approach
21. 187O Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Subgroup analyses from the phase III CAPItello-291 trial
22. 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial
23. 186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC)
24. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
25. P144 The Effect of Progesterone Receptor Expression Level to Predict Prognosis of Estrogen Receptor Positive/ HER2 Negative Young Breast Cancer: A Single-Center Prospective Cohort Study
26. Site U1510
27. Expedition 371 summary
28. Expedition 371 methods
29. Structural Properties and Mechanical Behavior of the 2 Step-Reinforced Al-Si/SiCp Metal Matrix Composite by Titanium-Fiber
30. Effect of Hafnium and Zirconium to Glass Forming Ability, Thermal Stability, Plasticity Deformation and Crystallization of Ni-Free Pentabasic Ti-Based Bulk Metallic Glasses
31. Effect of silk fibroin molecular weight on physical property of silk hydrogel
32. OD2-4 Efficient and noninvasive T cell therapy platform using autologous peripheral blood PD-1+CD8+ T cells instead of tumor-infiltrating lymphocytes in solid tumors: Ex vivo efficacy
33. A novel anti-cancer compound development targeting YAP-TEAD protein-protein interaction
34. Sorption of Lysozyme by HEMA Copolymer Hydrogels
35. Characterization Of The Graded Microstructure In Powder Sintered Porous Titanium
36. 225P MET-enriched circulating tumor cells and cell-free DNA concentration as significant independent predictors for progression in HR-positive HER2-negative metastatic breast cancer
37. 241P Genomic analysis of plasma cell-free DNA in patients with heavily pretreated HER-2+ metastatic breast cancer (MBC)
38. 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522
39. 217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
40. 144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study
41. 274TiP Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01
42. Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients
43. 174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis
44. PO-1219 Pattern of care for brain metastasis from breast cancer over the past 10 years in Korea
45. M044 Development of machine learning model for diagnostic disease prediction based on laboratory tests
46. 176P Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial
47. 5P Exploratory biomarker analysis from neoadjuvant atezolizumab, pertuzumab, trastuzumab plus docetaxel (NEO-PATH) in HER2+ early breast cancer
48. 175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
49. Optimization of organic light-emitting diode containing hydrochlorosilole electron transport layer through impedance spectroscopy analysis
50. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.